|                                  | MIC (mg/mL)   |              |              | Isolates n (%)            |            |                           |                   |
|----------------------------------|---------------|--------------|--------------|---------------------------|------------|---------------------------|-------------------|
| Antibiotic                       |               |              |              | Resistant genotype (n=69) |            | Sensitive genotype (n=31) |                   |
|                                  | Sensitive     | Intermediate | Resistant    | rrl mut                   | rrl wild,  | rrl wild,                 | rrl wild,         |
|                                  |               |              |              | (n=5)                     | erm(41)T28 | erm(41)C28                | <i>erm</i> (41) M |
|                                  |               |              |              |                           | (n=64)     | (n=6)                     | (n=25)            |
| CLA (resistant before induction) | ≤2            | 4            | <u>≥</u> 8   | 5 (100.0)                 | 27 (42.2)  | 0 (0.0)                   | 0 (0.0)           |
| CLA (resistant after induction)  | <u>&lt;</u> 2 | 4            | <u>≥</u> 8   | 5 (100.0)                 | 63 (98.4)  | 0 (0.0)                   | 1 (28.0)          |
| AMI (amikacin)                   | <u>≤</u> 16   | 32           | <u>≥</u> 64  | 0 (0)                     | 1 (1.6)    | 1 (16.7)                  | 0 (0)             |
| SXT (sulfonamides)               | ≤2            | $nrb^b$      | <u>≥</u> 4   | 2 (40.0)                  | 36 (56.3)  | 3 (50.0)                  | 15 (60.0)         |
| MXF (moxifloxacin)               | <u>≤</u> 1    | 2            | <u>≥</u> 4   | 5 (100.0)                 | 63 (98.4)  | 6 (100)                   | 24 (96.0)         |
| FOX (cefoxitin)                  | <u>≤</u> 16   | 32-64        | <u>≥</u> 128 | 1 (20.0)                  | 42 (65.6)  | 5 (83.3)                  | 17 (68.0)         |
| DOX (doxycycline)                | <u>≤</u> 1    | 2-4          | <u>≥</u> 8   | 5 (100.0)                 | 63 (98.4)  | 6 (100)                   | 25 (100.0)        |
| TGC (tigecycline)                | <u>≤</u> 1    | nrb          | nrb          | nd <sup>c</sup>           | nd         | nd                        | nd                |
| LZD (linezolid)                  | <u>≤</u> 8    | 16           | <u>≥</u> 32  | 3 (60.0)                  | 30 (46.9)  | 3 (50.0)                  | 10 (40.0)         |
| IMI (imipenem)                   | <u>≤</u> 4    | 8-16         | <u>≥</u> 32  | 5 (100.0)                 | 61 (95.3)  | 6 (100)                   | 24 (96.0)         |
| TOB (tobramycin)                 | <b>≤</b> 2    | 4            | <u>≥</u> 8   | 4 (80.0)                  | 56 (87.5)  | 6 (100)                   | 24 (96.0)         |

<sup>&</sup>lt;sup>a</sup>The *erm*(41) sequevar-dependent resistance of 100 *M. abscessus* isolates to the antibiotic indicated was determined by the microdilution method. The incubation time was 3 days (before induction) and 14 days (after induction) for CLA, and 3 days for the other antibiotics listed. MIC = minimum inhibitory concentration.

<sup>b</sup>no recommended breakpoint.


<sup>&</sup>lt;sup>c</sup>no data.

Supplementary Table 2. Relapse among patients infected with four *M. abscessus* genotype groups

|   | Resistar | nt group | Sensitive group |         |         |
|---|----------|----------|-----------------|---------|---------|
|   | rrl      | T28      | C28             | M       | P value |
|   | (n=5)    | (n=64)   | (n=6)           | (n=25)  |         |
| Duration of treatment, mean month                     | 10.5     | 8.1      | 6.0             | 1.0     | 0.257   |
| Patients defined as relapse*                          | 2 (40.0) | 8 (12.5) | 3 (50.0)        | 1 (4.0) | 0.009   |
| Sputum relapse after initial smear/culture conversion | 2 (40.0) | 7 (10.9) | 2 (33.3)        | 1 (4.0) | 0.049   |
| Radiological progressed without sputum relapse        | 2 (40.0) | 8 (12.5) | 3 (50.0)        | 0 (0)   | 0.003   |

<sup>\*</sup>Data are the number and (percentage) of patients infected with each genotype. Significant differences between the resistant and sensitive groups are indicated by a P value <0.05.

Supplementary Figure 1. Comparison of initial sputum smear/culture conversion rate among 4 genotypes



**Supplementary Figure 1**. Comparison of initial sputum smear/culture conversion rate among patients infected with the genotype groups indicated. Patients infected with the resistant, rrl mut and rrl wild/erm(41)T28 genotypes showed a significantly longer initial sputum medium conversion time than patients infected with the two sensitive genotypes, P = 0.008.